Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Five factor model of schizophrenia: replication across samples

J P Lindenmayer1, S Grochowski, R B Hyman

  • 1Department of Psychiatry, Albert Einstein College of Medicine, Bronx, NY, USA.

Schizophrenia Research
|February 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tardive dyskinesia versus tardive syndrome. What is in a name?

Parkinsonism & related disorders·2025
Same author

Effects of Clozapine on Neurocognitive Functions in Schizophrenia: A Naturalistic Comparison to Non-clozapine Antipsychotics.

Innovations in clinical neuroscience·2022
Same author

Transcranial direct-current stimulation in ultra-treatment-resistant schizophrenia.

Brain stimulation·2018
Same author

The relationship of cognitive improvement after cognitive remediation with social functioning in patients with schizophrenia and severe cognitive deficits.

Schizophrenia research·2017
Same author

Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo.

Schizophrenia research·2013
Same author

Long-acting injectable antipsychotics: focus on olanzapine pamoate.

Neuropsychiatric disease and treatment·2010
Same journal

Quality evaluation of randomized controlled trials of antipsychotic drugs for schizophrenia published in Chinese journals.

Schizophrenia research·2026
Same journal

FL-SDGIN: A federated graph learning approach for schizophrenia diagnosis integrating static and dynamic brain functional networks.

Schizophrenia research·2026
Same journal

Weight loss and gut microbial changes associated with semaglutide among people living with schizophrenia receiving clozapine or olanzapine: An open-label 24-week semaglutide intervention and 76-week trial.

Schizophrenia research·2026
Same journal

Converting negative symptom dimension scores across SANS and PANSS.

Schizophrenia research·2026
Same journal

Inflammation-associated alterations in mGluR transcript expression in the human nucleus accumbens independent of schizophrenia diagnosis.

Schizophrenia research·2026
Same journal

One social interaction after another: Dynamic modeling of social experience in schizophrenia.

Schizophrenia research·2026
See all related articles

Neuroleptic medication stabilizes schizophrenic symptoms, with the five-factor model remaining consistent whether patients are medicated or not. Discontinuing medication worsened overall psychopathology across all symptom dimensions.

Area of Science:

  • Psychiatry
  • Clinical Psychology
  • Neuroscience

Background:

  • Schizophrenia is a complex mental disorder characterized by diverse symptoms.
  • Understanding the factor structure of schizophrenic psychopathology is crucial for treatment and research.
  • Neuroleptic medications are a cornerstone of schizophrenia management.

Purpose of the Study:

  • To investigate the impact of neuroleptic medication on the factor structure of schizophrenic symptoms.
  • To determine the stability of the five-factor model of schizophrenia during medication withdrawal.

Main Methods:

  • Utilized data from 517 schizophrenic patients in a multicenter phase II drug study.
  • Administered the Positive and Negative Syndrome Scale (PANSS) before and after a one-week drug-free period.

Related Experiment Videos

  • Performed principal components analyses on PANSS data at both time points.

    • Main Results:

    • The five-factor model (negative, positive, cognitive, excitement, depression) consistently explained significant variance (51.7% and 56.2%) in schizophrenic symptoms.
    • Psychopathology significantly worsened after medication withdrawal, affecting total PANSS scores and individual components.
    • The proportional contribution of each symptom component to total psychopathology remained largely constant, indicating dimensional stability.

    Conclusions:

    • The five-factor model of schizophrenic psychopathology, as measured by the PANSS, is robust and valid.
    • Neuroleptic medication appears to stabilize the underlying dimensions of schizophrenic symptoms.
    • Medication withdrawal leads to a global worsening of psychopathology without altering the fundamental symptom structure.